2015 Q3 Form 10-Q Financial Statement

#000156459016028322 Filed on November 08, 2016

View on sec.gov

Income Statement

Concept 2015 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.460M
YoY Change 0.2%
% of Gross Profit
Research & Development $7.330M
YoY Change 35.69%
% of Gross Profit
Depreciation & Amortization $40.00K
YoY Change 33.33%
% of Gross Profit
Operating Expenses $9.790M
YoY Change 24.18%
Operating Profit -$9.828M
YoY Change 24.66%
Interest Expense $101.0K
YoY Change 405.0%
% of Operating Profit
Other Income/Expense, Net -$15.00K
YoY Change
Pretax Income -$9.910M
YoY Change 25.92%
Income Tax
% Of Pretax Income
Net Earnings -$9.912M
YoY Change 26.01%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$4.235M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.90M
YoY Change 15.78%
Cash & Equivalents $32.21M
Short-Term Investments $17.70M
Other Short-Term Assets $1.500M
YoY Change 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $51.40M
YoY Change 16.66%
LONG-TERM ASSETS
Property, Plant & Equipment $300.0K
YoY Change 61.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K
YoY Change -44.98%
Total Long-Term Assets $12.00M
YoY Change -0.87%
TOTAL ASSETS
Total Short-Term Assets $51.40M
Total Long-Term Assets $12.00M
Total Assets $63.40M
YoY Change 12.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.900M
YoY Change 151.24%
Accrued Expenses $8.900M
YoY Change 83.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $1.500M
YoY Change
Total Short-Term Liabilities $13.52M
YoY Change 79.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $13.00M
YoY Change
Total Long-Term Liabilities $13.00M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $13.52M
Total Long-Term Liabilities $13.00M
Total Liabilities $29.90M
YoY Change 173.92%
SHAREHOLDERS EQUITY
Retained Earnings -$264.8M
YoY Change 16.24%
Common Stock $298.3M
YoY Change 9.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.54M
YoY Change
Total Liabilities & Shareholders Equity $63.44M
YoY Change 12.95%

Cashflow Statement

Concept 2015 Q3
OPERATING ACTIVITIES
Net Income -$9.912M
YoY Change 26.01%
Depreciation, Depletion And Amortization $40.00K
YoY Change 33.33%
Cash From Operating Activities -$8.260M
YoY Change 53.82%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities $4.460M
YoY Change 57.04%
Cash From Investing Activities $4.430M
YoY Change 57.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.82M
YoY Change 582.95%
NET CHANGE
Cash From Operating Activities -8.260M
Cash From Investing Activities 4.430M
Cash From Financing Activities 14.82M
Net Change In Cash 10.99M
YoY Change -2917.95%
FREE CASH FLOW
Cash From Operating Activities -$8.260M
Capital Expenditures -$30.00K
Free Cash Flow -$8.230M
YoY Change 54.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Trading Symbol
TradingSymbol
MSTX
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
17929000
CY2015Q4 mstx In Process Research And Development
InProcessResearchAndDevelopment
8549000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1430000
CY2015Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
10991000
CY2015Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
25000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
947000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
15000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1294000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
160000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2140000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
6000
mstx Cash Proceeds From Warrant Exercises
CashProceedsFromWarrantExercises
408000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
5000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15894000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16846000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2531000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3601000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35808000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32207000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and assumptions, including estimates related to R&amp;D expenses, in-process research and development (&#8220;IPR&amp;D&#8221;), goodwill, and share-based compensation expenses. We base our estimates on historical experience and various other relevant assumptions we believe to be reasonable under the circumstances. Actual results may differ from these estimates.</p></div>
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-39400000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-32900000
CY2016Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
27000000
CY2016Q3 mstx Working Capital
WorkingCapital
7400000
CY2016Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11556000
CY2015Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11556000
us-gaap Goodwill Impaired Change In Estimate Description
GoodwillImpairedChangeInEstimateDescription
A quantitative assessment of goodwill utilizes a two-step approach. We first compared our carrying value, including goodwill, to our estimated fair value. If the carrying value had exceeded the estimated fair value, we would have performed Step 2 to measure the amount of any impairment charge. As the carrying value did not exceed estimated fair value, we did not perform Step 2 and concluded that no impairment charge for goodwill is required.
CY2016Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
0
CY2016Q3 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
6425000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
4000
CY2016Q3 us-gaap Capital Lease Obligations
CapitalLeaseObligations
40000
us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
The interest rate for the principal balance under the Loan Agreement is the greater of (i) 8.95% plus the prime rate as reported in The Wall Street Journal minus 3.25%, and (ii) 8.95%, determined on a daily basis.
CY2015 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.0895
CY2015 us-gaap Debt Instrument Interest Rate Increase Decrease
DebtInstrumentInterestRateIncreaseDecrease
-0.0325
CY2015Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
712500
us-gaap Line Of Credit Facility Frequency Of Payment And Payment Terms
LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms
The interest rate for the principal balance under the Loan Agreement is the greater of (i) 8.95% plus the prime rate as reported in The Wall Street Journal minus 3.25%, and (ii) 8.95%, determined on a daily basis. Monthly payments under the Loan Agreement were interest only until July 1, 2016. On July 1, August 1, and September 1, 2016 we made equal monthly payments against the principal balance in addition to the interest amounts. We are required to repay the loan in equal monthly installments of principal and interest on the first business day of each month through the scheduled maturity date of January 1, 2019.
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
544000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1951000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2122000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
8151263
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1151393
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
29896598
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.42
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.98
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.67
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
us-gaap Interest Paid
InterestPaid
1042000
us-gaap Interest Paid
InterestPaid
26000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
26000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
393000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
22000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
34000
mstx Receivable For Warrant Exercise
ReceivableForWarrantExercise
65000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
35000
mstx Debt Issuance Costs Included In Accounts Payable And Accrued Liabilities
DebtIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
33000
CY2016Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
8000000
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
29090910
mstx Description Of Fixed Combination Of Shares And Warrant Offered And Sold To Public
DescriptionOfFixedCombinationOfSharesAndWarrantOfferedAndSoldToPublic
each consisting of one share of our common stock and one warrant to purchase one share of our common stock.
CY2016Q1 mstx Number Of Securities In Each Unit
NumberOfSecuritiesInEachUnit
1
CY2016Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2016Q1 mstx Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
7300000
CY2016Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.42
CY2016Q1 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2016-08-17
CY2016Q1 mstx Class Of Warrant Or Rights Expiration Date
ClassOfWarrantOrRightsExpirationDate
2021-02-16
CY2015Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2272727
CY2015Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.275
CY2015Q3 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2020-08-11
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
500000
CY2016Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
91281302

Files In Submission

Name View Source Status
0001564590-16-028322-index-headers.html Edgar Link pending
0001564590-16-028322-index.html Edgar Link pending
0001564590-16-028322.txt Edgar Link pending
0001564590-16-028322-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mstx-10q_20160930.htm Edgar Link pending
mstx-20160930.xml Edgar Link completed
mstx-20160930.xsd Edgar Link pending
mstx-20160930_cal.xml Edgar Link unprocessable
mstx-20160930_def.xml Edgar Link unprocessable
mstx-20160930_lab.xml Edgar Link unprocessable
mstx-20160930_pre.xml Edgar Link unprocessable
mstx-ex311_6.htm Edgar Link pending
mstx-ex312_7.htm Edgar Link pending
mstx-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending